• by admin
• (0) Comments

Diabetes Care Gets a Boost in Budget 2026

Dr. G. Krishna Mohan Reddy, Senior Consultant Physician and Diabetologist, Yashoda Hospitals, Hyderabad 

As a diabetologist, I see Budget 2026 as a strong step toward reshaping India’s healthcare landscape. The government’s plan to set up five medical value tourism hubs will not only attract global patients but also improve standards of care for chronic conditions like diabetes, which require long‑term management and advanced facilities.

The launch of Biotech SHAKTI and the ₹10,000 crore push for biopharma manufacturing is particularly relevant for non‑communicable diseases (NCDs). Diabetes care increasingly depends on biologics, insulin analogues, and innovative therapies. Strengthening India’s biopharma ecosystem will make these treatments more affordable and accessible, especially for patients in tier 2 and tier 3 cities.

Equally important is the focus on manpower. Training 1.5 lakh caregivers and upgrading allied health institutions to add another 1.5 lakh professionals in five years will directly benefit diabetes care. Managing diabetes is not just about prescribing medicines—it requires dieticians, educators, nurses, and physiotherapists who can guide patients in lifestyle changes, adherence, and complication prevention.

The proposal to establish three new All India Institutes of Ayurveda also opens opportunities for integrative care. Many patients seek holistic approaches, and combining modern medicine with evidence‑based traditional practices can improve outcomes in diabetes management.

Strengthening the Central Drug Standard Control Organisation and setting up 1,000 clinical trial sites will ensure global standards in drug development and safety. This is crucial for diabetes, where newer therapies must be tested and approved quickly to meet patient needs.

Most importantly, the budget’s emphasis on affordable healthcare for diabetes, cancer, and autoimmune disorders reflects a patient‑centric vision. Subsidising diagnostics, improving access to insulin, and expanding preventive programmes will reduce the burden of complications and hospitalisations.

Healthcare is not an expense—it is an investment in national productivity. By focusing on prevention, affordability, and innovation, India can position itself as a global leader in NCD care. Budget 2026 is a welcome move, but timely implementation will be key to ensuring that millions of Indians living with diabetes benefit from these initiatives.

Disclaimer: The views and opinions expressed in this interview are those of the author and do not reflect the official position of any medical body or organization. 
The author is not a medical doctor; however, the insights shared are based on over a decade of working experience in the healthcare sector start-ups. 
Readers should consult with a qualified healthcare professional for medical advice or information related to their specific situation.

Please follow our page Aristocrat Media for more updates 
For Enquiries connect us on:
marketing@aristocrat-media.com